Opportunity Information: Apply for RFA MH 13 070
Apply for RFA MH 13 070
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition National NeuroAIDS Tissue Consortium (NNTC) Clinical Sites (U24)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders.
- This funding opportunity was created on Jul 5, 2012 and posted on Jul 5, 2012.
- Applicants must submit their applications by Sep 4, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $3,100,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- Other Eligible Applicants include the following Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This grant opportunity, titled "Limited Competition National NeuroAIDS Tissue Consortium (NNTC) Clinical Sites (U24)" (Funding Opportunity Number RFA-MH-13-070), was a National Institutes of Health (NIH) funding announcement led by the National Institute of Mental Health (NIMH) in partnership with the National Institute of Neurological Disorders and Stroke (NINDS). It used the U24 cooperative agreement mechanism, which means funded sites would not operate as independent, stand-alone projects. Instead, they would be expected to work closely with NIH program staff and in active coordination with the NNTC Data Coordinating Center (DCC) and the broader consortium. The overall purpose was to continue the work of the NNTC Clinical Sites previously supported under an earlier solicitation (RFA MH 08-021), keeping the consortium functioning as a national research resource focused on HIV-related nervous system disease in the era of modern antiretroviral therapy.
At its core, the NNTC exists to support research on the biological and clinical mechanisms that drive neurological and neuropsychiatric complications of HIV infection, particularly in late-stage disease. The Clinical Sites serve as the front line of this resource. They identify and follow HIV-infected participants who are willing to participate in organ donation, and they systematically gather both clinical information and biologic materials that can be used by outside investigators. The emphasis is not simply on collecting tissue, but on pairing high-quality specimens with well-characterized neuromedical and neuropsychiatric data, so researchers can ask detailed questions about how HIV and its treatments affect the brain and nervous system over time.
The scope of work for the Clinical Sites includes several linked responsibilities. Sites are expected to perform clinical and neuropsychiatric assessments during participants lives, and then, when donation occurs, collect brain and other neurologic tissues as well as relevant fluids. In addition to specimen recovery and processing, the sites also conduct neuropathological diagnostic work and other laboratory assessments needed to characterize the materials. Just as important, they must transmit selected data produced through these activities into the centralized NNTC database, which is maintained by the consortiums Data Coordinating Center. This makes the program a structured, shared infrastructure: clinical sites generate standardized specimens and data, and the DCC curates, manages, and distributes the information and materials so they can be accessed and used by qualified researchers.
A defining feature of the announcement is that it is a limited competition. In practical terms, that signals the applicant pool was restricted to a specified set of eligible organizations described in the full FOA, rather than being open to all comers. The eligibility rules also made clear that foreign institutions could not apply, and foreign components (as NIH defines them) were not allowed. The opportunity did not require cost sharing or matching funds, which is typical for many NIH research infrastructure programs. The program anticipated making about four awards, with an estimated total funding level of about $3.1 million for the competition, reflecting its intention to support a small number of major clinical site hubs rather than many smaller awards.
This FOA was also explicitly paired with a companion announcement seeking a separate award for the NNTC Data Coordinating Center (RFA-MH-13-071). That division of labor matters because it clarifies how NIH intended the consortium to function: the clinical sites are responsible for participant engagement, clinical characterization, donation logistics, specimen acquisition, and local diagnostic work, while the DCC provides the central informatics backbone and coordination needed for consistent data standards and broad sharing with the research community. The end result is a national platform designed to keep a steady pipeline of high-value, well-annotated neuroHIV specimens and clinical data available for studies on pathophysiology and disease mechanisms, particularly those relevant to nervous system complications that persist even in the antiretroviral era.
Administratively, this was a discretionary health funding opportunity using a cooperative agreement funding instrument. It was posted July 5, 2012, with an application due date of September 4, 2012, and it was later archived on October 5, 2012. The associated CFDA program numbers were 93.242 (Mental Health Research Grants) and 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders), reflecting the joint mental health and neurology focus of the consortiums mission.
FAQs: Limited Competition National NeuroAIDS Tissue Consortium (NNTC) Clinical Sites (U24) - RFA-MH-13-070
What is this grant opportunity?
This opportunity is the NIH funding announcement titled "Limited Competition National NeuroAIDS Tissue Consortium (NNTC) Clinical Sites (U24)" with Funding Opportunity Number (FOA) RFA-MH-13-070.
Which NIH institutes led and partnered on this FOA?
The announcement was led by the National Institute of Mental Health (NIMH) in partnership with the National Institute of Neurological Disorders and Stroke (NINDS).
What funding mechanism does this FOA use?
It uses the U24 cooperative agreement mechanism.
What does a U24 cooperative agreement mean for how the work is managed?
A U24 cooperative agreement means the funded clinical sites would not operate as independent, stand-alone projects. They are expected to work closely with NIH program staff and in active coordination with the NNTC Data Coordinating Center (DCC) and the broader consortium.
What is the overall purpose of funding NNTC Clinical Sites under this FOA?
The purpose is to continue the work of NNTC Clinical Sites previously supported under an earlier solicitation (RFA MH 08-021) and to keep the consortium functioning as a national research resource focused on HIV-related nervous system disease in the era of modern antiretroviral therapy.
What is the NNTC and what does it support?
The NNTC exists to support research on the biological and clinical mechanisms that drive neurological and neuropsychiatric complications of HIV infection, with particular emphasis on late-stage disease.
What role do the Clinical Sites play in the NNTC?
Clinical Sites serve as the front line of the resource. They identify and follow HIV-infected participants willing to participate in organ donation and systematically gather clinical information and biologic materials for use by outside investigators.
Is the focus only on collecting tissue?
No. The emphasis is on pairing high-quality specimens with well-characterized neuromedical and neuropsychiatric data so researchers can examine how HIV and its treatments affect the brain and nervous system over time.
What participant-related activities are Clinical Sites expected to perform during participants' lives?
Clinical Sites are expected to perform clinical and neuropsychiatric assessments while participants are living.
What happens at the time of donation, according to the FOA description?
When donation occurs, Clinical Sites collect brain and other neurologic tissues as well as relevant fluids.
Beyond specimen recovery, what laboratory or diagnostic responsibilities do Clinical Sites have?
Sites are responsible for specimen recovery and processing and also conduct neuropathological diagnostic work and other laboratory assessments needed to characterize the materials.
What are the data-sharing expectations for Clinical Sites?
Clinical Sites must transmit selected data produced through their activities into the centralized NNTC database maintained by the Data Coordinating Center.
What is the role of the NNTC Data Coordinating Center (DCC) in this consortium model?
The DCC maintains the centralized NNTC database and provides the central informatics backbone and coordination needed for consistent data standards and broad sharing with the research community.
How does this FOA relate to the DCC funding?
This FOA was paired with a companion announcement that sought a separate award for the NNTC Data Coordinating Center (RFA-MH-13-071). The clinical sites and the DCC have distinct responsibilities that work together as a structured, shared infrastructure.
What is meant by "limited competition" for this FOA?
"Limited competition" means the applicant pool was restricted to a specified set of eligible organizations described in the full FOA, rather than being open to all applicants.
Are foreign institutions eligible to apply?
No. The eligibility rules stated that foreign institutions could not apply.
Are foreign components allowed under this FOA?
No. Foreign components (as NIH defines them) were not allowed.
Is cost sharing or matching required?
No. The opportunity did not require cost sharing or matching funds.
How many awards were anticipated?
The program anticipated making about four awards.
What was the estimated total funding level for the competition?
The estimated total funding level was about $3.1 million.
What type of program structure does this funding support?
It supports a consortium structure in which a small number of major clinical site hubs generate standardized specimens and data, and a central DCC curates, manages, and helps distribute information and materials for use by qualified researchers.
What is the scientific emphasis of the resource in the context of HIV treatment advances?
The resource is designed to study nervous system complications of HIV that persist in the era of modern antiretroviral therapy, including neurological and neuropsychiatric complications and their underlying mechanisms.
When was this FOA posted and when were applications due?
It was posted on July 5, 2012, and the application due date was September 4, 2012.
When was the FOA archived?
The FOA was archived on October 5, 2012.
What CFDA program numbers are associated with this opportunity?
The associated CFDA numbers were 93.242 (Mental Health Research Grants) and 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders).
How do the CFDA numbers reflect the focus of the program?
They reflect the joint mental health and neurology focus of the consortium's mission, aligning with NIMH and NINDS involvement.
What kind of funding opportunity is this described as administratively?
It was described as a discretionary health funding opportunity using a cooperative agreement funding instrument.
Browse more opportunities from the same category: Health
Next opportunity: National NeuroAIDS Tissue Consortium (NNTC) Data Coordinating Center (DCC) (U24)
Previous opportunity: Tuberculosis Regional Training and Medical Consultation Centers
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA MH 13 070
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA MH 13 070) also looked into and applied for these:
| Funding Opportunity |
|---|
| National NeuroAIDS Tissue Consortium (NNTC) Data Coordinating Center (DCC) (U24) Apply for RFA MH 13 071 Funding Number: RFA MH 13 071 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| NIAMS Clinical Trial Outcomes Instrument Development Grant Program (U01) Apply for RFA AR 13 004 Funding Number: RFA AR 13 004 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
| NIMHD Transdisciplinary Collaborative Centers for Health Disparities Research (U54) Apply for RFA MD 12 007 Funding Number: RFA MD 12 007 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| Institutional Clinical and Translational Science Award (U54) Apply for RFA TR 12 006 Funding Number: RFA TR 12 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Affordable Care Act Maternal, Infant and Early Childhood Home Visiting Program Apply for HRSA 12 156 Funding Number: HRSA 12 156 Agency: Health Resources and Services Administration Category: Health Funding Amount: $3,000,000 |
| Identification and Analysis of Causal Variants Follow Up on Genome Wide Association Studies for Arthritis and Musculoskeletal and Skin Diseases (R21) Apply for PAR 12 230 Funding Number: PAR 12 230 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Identification and Analysis of Causal Variants Follow Up on Genome Wide Association Studies for Arthritis and Musculoskeletal and Skin Diseases (R01) Apply for PAR 12 236 Funding Number: PAR 12 236 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Unconventional Roles of Ethanol Metabolizing Enzymes, Metabolites, and Cofactors in Health and Disease (R21) Apply for PA 12 234 Funding Number: PA 12 234 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Unconventional Roles of Ethanol Metabolizing Enzymes, Metabolites, and Cofactors in Health and Disease (R01) Apply for PA 12 235 Funding Number: PA 12 235 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Specialized Neuroscience Research Program (SNRP) (U54) Apply for RFA NS 13 004 Funding Number: RFA NS 13 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Stem Cells and Alcohol induced Tissue Injuries (R01) Apply for PA 12 233 Funding Number: PA 12 233 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Stem Cells and Alcohol induced Tissue Injuries (R21) Apply for PA 12 232 Funding Number: PA 12 232 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Tobacco Centers of Regulatory Science for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (P50) Apply for RFA DA 13 003 Funding Number: RFA DA 13 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition Renewal of Centers of Biomedical Research Excellence (COBRE)P20 Apply for PAR 12 224 Funding Number: PAR 12 224 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinically Relevant Genetic Variants Resource A Unified Approach for Identifying Genetic Variants for Clinical Use (U01) Apply for RFA HG 12 016 Funding Number: RFA HG 12 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Fatigability, Activity Limitations, and Bioenergetics in Aging (R21) Apply for PA 12 225 Funding Number: PA 12 225 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Fatigability, Activity Limitations, and Bioenergetics in Aging (R03) Apply for PA 12 226 Funding Number: PA 12 226 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Fatigability, Activity Limitations, and Bioenergetics in Aging (R01) Apply for PA 12 227 Funding Number: PA 12 227 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Organizations for Chronic Disease Prevention and Health Promotion CDC RFA DP10 1008 Apply for CDC RFA DP10 10080301SUPP12 Funding Number: CDC RFA DP10 10080301SUPP12 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,500,000 |
| Alcohol Research Resource Awards (R24) Apply for PAR 12 237 Funding Number: PAR 12 237 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA MH 13 070", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.